Multiple Endocrine Neoplasia Type 1
Associated Genetic Biomarkers
NCI Definition: Multiple endocrine neoplasia caused by inactivation of the tumor suppressor gene MEN-1. Patients may develop hyperparathyroidism and parathyroid gland adenomas, pituitary gland adenomas, pancreatic islet cell neoplasms, and carcinoid tumors. 
There are 2 clinical trials for multiple endocrine neoplasia type 1, of which 2 are open and 0 are completed or closed. Of the trials that contain multiple endocrine neoplasia type 1 as an inclusion criterion, 1 is phase 2 (1 open) and 1 is phase 3 (1 open).
MEN1 is the most frequent gene inclusion criterion for multiple endocrine neoplasia type 1 clinical trials .
Everolimus, lenvatinib, and observation are the most common interventions in multiple endocrine neoplasia type 1 clinical trials.
Significant Genes in Multiple Endocrine Neoplasia Type 1
MEN1 is an inclusion eligibility criterion in 1 clinical trial for multiple endocrine neoplasia type 1, of which 1 is open and 0 are closed. Of the trial that contains MEN1 status and multiple endocrine neoplasia type 1 as inclusion criteria, 1 is phase 3 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.